  shares in aetna inc nyseaet acquired by iguana healthcare management llc  bnb daily daily ratings  news for aetna inc complete the form below to receive the latest headlines and analysts recommendationsfor aetna inc with our free daily email newsletter follow bnbdailynews recent posts  shares in aetna inc nyseaet acquired by iguana healthcare management llc henry schein inc nasdaqhsic stake decreased by invictus rg axalta coating systems ltd nasdaqaxta stake decreased by amalgamated bank amalgamated bank acquires  shares of flir systems inc nasdaqflir invictus rg has  position in icon plc iclr bidaskclub upgrades planet fitness inc plnt to buy oppenheimer asset management inc acquires shares of  o’reilly automotive inc orly oppenheimer asset management inc acquires shares of  nokia corporation nok two sigma securities llc acquires new position in arcelormittal mt state street corp boosts stake in marriott international mar state street corp has  million stake in autozone inc azo church  dwight company inc chd shares bought by state street corp rite aid corporation rad announces quarterly earnings results national bank financial cuts stepan company scl price target to  oppenheimer  co inc has  position in carbonite inc carb bank of america corp de decreases stake in atmos energy corporation ato two sigma securities llc cuts stake in constellation brands inc stz liberum capital reiterates “buy” rating for rps group plc rps polypipe group plc plp pt raised to gbx  at jefferies group llc aegion corp aegn shares sold by oppenheimer  co inc  shares in aetna inc nyseaet acquired by iguana healthcare management llc posted by stefani robinson on jul th   no comments iguana healthcare management llc purchased a new stake in shares of aetna inc nyseaet during the first quarter according to its most recent disclosure with the securities and exchange commission sec the firm purchased  shares of the company’s stock valued at approximately  aetna makes up  of iguana healthcare management llc’s holdings making the stock its th largest position other large investors have also recently bought and sold shares of the company blackrock inc raised its stake in aetna by  in the first quarter blackrock inc now owns  shares of the company’s stock valued at  after buying an additional  shares in the last quarter orbis allan gray ltd bought a new stake in shares of aetna during the fourth quarter valued at  vanguard group inc raised its stake in shares of aetna by  in the first quarter vanguard group inc now owns  shares of the company’s stock valued at  after buying an additional  shares in the last quarter aqr capital management llc raised its stake in shares of aetna by  in the first quarter aqr capital management llc now owns  shares of the company’s stock valued at  after buying an additional  shares in the last quarter finally ubs asset management americas inc raised its stake in shares of aetna by  in the first quarter ubs asset management americas inc now owns  shares of the company’s stock valued at  after buying an additional  shares in the last quarter  of the stock is currently owned by institutional investors and hedge funds aetna inc aet traded down  during trading on monday hitting  the company had a trading volume of  shares the company has a market capitalization of  billion a pricetoearnings ratio of  and a beta of  the firm has a day moving average of  and a  day moving average of  aetna inc has a month low of  and a month high of  get aetna inc alerts aetna nyseaet last announced its quarterly earnings data on tuesday may nd the company reported  eps for the quarter topping analysts’ consensus estimates of  by  aetna had a return on equity of  and a net margin of  the business had revenue of  billion during the quarter compared to analysts’ expectations of  billion during the same period in the previous year the firm earned  earnings per share the firm’s quarterly revenue was down  compared to the same quarter last year on average equities research analysts forecast that aetna inc will post  earnings per share for the current year the business also recently disclosed a quarterly dividend which will be paid on friday july th investors of record on thursday july th will be paid a dividend of  per share the exdividend date of this dividend is tuesday july th this represents a  dividend on an annualized basis and a dividend yield of  aetna’s dividend payout ratio dpr is presently  illegal activity warning this news story was reported by bnb daily and is the property of of bnb daily if you are accessing this news story on another publication it was illegally copied and republished in violation of united states and international trademark and copyright laws the legal version of this news story can be viewed at httpswwwbaseballnewsblogcomiguanahealthcaremanagementllcinvestsmillioninaetnaincnyseaetupdatedhtml several equities research analysts have weighed in on the company bidaskclub lowered aetna from a “strongbuy” rating to a “buy” rating in a research report on wednesday july th deutsche bank ag increased their target price on aetna from  to  and gave the stock a “hold” rating in a research report on thursday july th credit suisse group reaffirmed an “outperform” rating and issued a  target price up from  on shares of aetna in a research report on thursday july th zacks investment research raised aetna from a “hold” rating to a “buy” rating and set a  target price on the stock in a research report on tuesday july th finally citigroup inc began coverage on aetna in a research report on wednesday june th they issued a “buy” rating and a  target price on the stock seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company the stock has an average rating of “buy” and an average price target of  in other aetna news chairman mark t bertolini sold  shares of the business’s stock in a transaction dated wednesday may th the stock was sold at an average price of  for a total value of  following the completion of the transaction the chairman now directly owns  shares of the company’s stock valued at  the transaction was disclosed in a legal filing with the sec which can be accessed through this hyperlink also evp margaret m mccarthy sold  shares of the business’s stock in a transaction dated wednesday june th the shares were sold at an average price of  for a total value of  following the completion of the transaction the executive vice president now directly owns  shares of the company’s stock valued at  the disclosure for this sale can be found here  of the stock is owned by insiders aetna company profile aetna inc is a diversified healthcare benefits company the company operates through three segments health care group insurance and large case pensions it offers a range of traditional voluntary and consumerdirected health insurance products and related services including medical pharmacy dental behavioral health group life and disability plans medical management capabilities medicaid healthcare management services medicare advantage and medicare supplement plans workers’ compensation administrative services and health information technology hit products and services receive news  ratings for aetna inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for aetna inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ﻿ iguana healthcare management llc has  million stake in nuvasive inc nuva  chaffey breeze daily ratings  news for nuvasive inc complete the form below to receive the latest headlines and analysts recommendationsfor nuvasive inc with our free daily email newsletter follow chaffeybreeze recent posts jefferies group llc reiterates “buy” rating for ulta beauty inc ulta on deck capital inc nyseondk upgraded by zacks investment research to buy heartland express inc nasdaqhtld earns underweight rating from morgan stanley domtar corporation nyseufs earns underweight rating from analysts at keycorp braskem sa bak upgraded to “buy” at bidaskclub bidaskclub upgrades brunswick corporation bc to “strongbuy” burlington stores inc burl upgraded by bidaskclub to buy argus boosts constellation brands inc nysestz price target to  gol linhas aereas inteligentes sa nysegol lifted to neutral at citigroup inc wedbush downgrades capital one financial corporation cof to underperform zacks investment research lowers colony starwood homes nysesfr to sell realnetworks inc nasdaqrnwk lifted to hold at zacks investment research mastercard incorporated nysema upgraded to buy by zacks investment research ishares jpmorgan usd emer mkt bnd fd etf to issue monthly dividend of  emb calamos global total return fund cgo announces  monthly dividend dlh holdings corp dlhc lowered to “hold” at valuengine mobileiron’s mobl “buy” rating reiterated at northland securities teachers advisors llc has  million stake in trimble navigation ltd nasdaqtrmb gibraltar industries inc nasdaqrock shares sold by tiaa cref investment management llc trinity mirror plc tni set to announce quarterly earnings on monday iguana healthcare management llc has  million stake in nuvasive inc nuva posted by harper lund on jul th   no comments iguana healthcare management llc reduced its stake in shares of nuvasive inc nasdaqnuva by  during the first quarter according to its most recent disclosure with the sec the firm owned  shares of the medical device company’s stock after selling  shares during the period nuvasive makes up about  of iguana healthcare management llc’s investment portfolio making the stock its nd largest position iguana healthcare management llc owned approximately  of nuvasive worth  at the end of the most recent quarter other hedge funds and other institutional investors also recently modified their holdings of the company westside investment management inc acquired a new stake in shares of nuvasive during the first quarter worth  neuburgh advisers llc increased its position in shares of nuvasive by  in the first quarter neuburgh advisers llc now owns  shares of the medical device company’s stock worth  after buying an additional  shares in the last quarter spiderrock advisors llc acquired a new position in shares of nuvasive during the first quarter worth  elkfork partners llc acquired a new position in shares of nuvasive during the fourth quarter worth  finally glen harbor capital management llc boosted its stake in shares of nuvasive by  in the first quarter glen harbor capital management llc now owns  shares of the medical device company’s stock valued at  after buying an additional  shares during the last quarter get nuvasive inc alerts shares of nuvasive inc nasdaqnuva opened at  on friday the stock has a market capitalization of  billion a pricetoearnings ratio of  and a beta of  the stock has a  day moving average price of  and a  day moving average price of  nuvasive inc has a year low of  and a year high of  nuvasive nasdaqnuva last issued its earnings results on tuesday april th the medical device company reported  earnings per share for the quarter beating analysts’ consensus estimates of  by  the company had revenue of  million for the quarter compared to the consensus estimate of  million nuvasive had a return on equity of  and a net margin of  the firm’s quarterly revenue was up  on a yearoveryear basis during the same quarter in the prior year the company earned  eps equities research analysts anticipate that nuvasive inc will post  eps for the current year warning this article was first posted by chaffey breeze and is owned by of chaffey breeze if you are reading this article on another publication it was stolen and reposted in violation of us  international copyright and trademark laws the original version of this article can be accessed at httpswwwchaffeybreezecomnuvasiveincnuvastakereducedbyiguanahealthcaremanagementllcupdatedupdatedhtml several equities research analysts recently commented on nuva shares bmo capital markets reissued a “buy” rating and issued a  price target on shares of nuvasive in a research note on tuesday april th barclays plc increased their target price on nuvasive from  to  and gave the stock an “overweight” rating in a report on monday april th canaccord genuity reiterated a “buy” rating and issued a  price target up previously from  on shares of nuvasive in a report on wednesday april th zacks investment research upgraded nuvasive from a “sell” rating to a “hold” rating in a report on thursday april th finally thestreet upgraded nuvasive from a “c” rating to a “b” rating in a research note on wednesday may rd three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company the stock has a consensus rating of “buy” and a consensus price target of  nuvasive company profile nuvasive inc is a medical device company the company focuses on developing minimallydisruptive surgical products and procedurallyintegrated solutions for the spine surgery its product portfolio focuses on applications for spine fusion surgery including biologics used to aid in the spinal fusion process receive news  ratings for nuvasive inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for nuvasive inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website write or find wallet hub reviews   the top destination for financial reviews the top destination for financial reviews latest reviews all financial companies  professionals banks attorneys financial advisors insurance companies insurance broker mortgage companies mortgage brokers popular companies get your free credit score  report join wallethub   free  unlimited credit reports  unlimited credit scores  credit monitoring protection  credit improvement tips  automatically finds savings sign up for free no credit card needed iguana healthcare management llc company profile  bloomberg feedback iguana healthcare management llc private company company profile sector financials industry asset management subindustry investment management iguana healthcare management llc operates as an investment management company the company invests in pharmaceuticals biotechnology medical devices diagnostics and healthcare industries iguana healthcare management serves customers in the state of new york corporate information address  th avenue suite  new york ny  united states phone  fax  web url wwwiguanahealthcarecom from the web key executives norman stanton schleifer cfocoochief compliance ofcr stuart t weisbrod chief invsmt officerfounder sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data stuart terry weisbrod  founder  chief investment officer at iguana healthcare management llc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink stuart terry weisbrod founder  chief investment officer at iguana healthcare management llc overview relationships paths education career history boards  committees political donations transactions stuart terry weisbrod founder  chief investment officer at iguana healthcare management llc overview notable companies iguana healthcare partners llc iguana healthcare management llc merlin biomed group hedge funds board seats  number of relationships this person is connected to  people relationships see details norman schleifer chief financial officer chief operating officer cco at iguana healthcare management llc daniel joonbyung chai partner  portfolio manager at iguana healthcare management llc david ezra shahmoon senior analyst at iguana healthcare management llc oren gabriel livnat analyst at h c wainwright  co llc christopher l eisgruber president at princeton university katherine t rohrer vice provost emeritus at princeton university alan patten associate chair department of politics at princeton university hae bin kim ucouncil executive representative at princeton university hendrik hartog director program in american studies at princeton university dean mary baum associate dean at princeton university see  more listings with relsci professional start my free trial ➤ see  more paths to stuart terry weisbrod stuart terry weisbrod you connections via relationship science stuart terry weisbrod sync your contacts to see how you can connect with stuart terry weisbrod start my free trial ➤ see more educational background graduate  class of   princeton university princeton university is a vibrant community of scholarship and learning that stands in the nations service and in the service of all nations chartered in  princeton is the fourtholdest college in the united states princeton is an independent coeducational nondenominational institution that provides undergraduate and graduate instruction in the humanities social sciences natural sciences and engineering as a worldrenowned research university princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding at the same time princeton is distinctive among research universities in its commitment to undergraduate teaching today more than  faculty members instruct approximately  undergraduate students and  graduate students the universitys generous financial aid program ensures that talented students from all economic backgrounds can afford a princeton education undergraduate degree  class of   colgate university founded in  colgate university is a highly selective residential liberal arts institution distinguished by academic excellence and interdisciplinary inquiry located on a beautiful campus in upstate new york colgate takes pride in the active engagement of its students and faculty in local national and global communities graduate  columbia university columbia university is one of the worlds most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields the university recognizes the importance of its location in new york city and seeks to link its research and teaching to the vast resources of a great metropolis it seeks to attract a diverse and international faculty and student body to support research and teaching on global issues and to create academic relationships with many countries and regions it expects all areas of the university to advance knowledge and learning at the highest level and to convey the products of its efforts to the world mba in finance  columbia university  columbia business school columbia business school cbs is the business school of columbia university in manhattan new york city it was established in  to provide business training and professional preparation for undergraduate and graduate columbia university students it is one of six ivy league business schools and its admission process is among the most selective of top business schools career history founder current iguana healthcare partners llc iguana healthcare partners llc provides investment advice the company was founded by stuart t weisbrod and is headquartered in new york ny founder  chief investment officer   current iguana healthcare management llc iguana healthcare management healthcare’s investment objective is for its clients to maximum returns from investing long and short globally in public companies in the life sciences industry while actively managing both sector and global risk with an eye on capital preservation the broad base of investment opportunities includes but is not limited to companies focusing on biotechnology branded pharmaceuticals generic pharmaceutics medical devices and medical supplies healthcare service providers and healthcare information technology iguana healthcare clients’ portfolios are constructed using a multifactorial approach with a focus on balancing risk and liquidity with expected returns on individual stocks and with their impact on upon overall portfolio concentration portfolios are constructed stockbystock and not subsector by subsector founder    merlin biomed group hedge funds merlin biomed invests globally in public and private healthcare companiesthe firms hedge funds and longterm appreciation fund seek maximum capital appreciation from broadbased global investment in small mid and largecap public and private companies in the areas of biotechnology pharmaceuticals medical devices healthcare services and research productsservices this investment objective is characterized by an intensive researchoriented fundamental bottomup approach with a focus on new product innovation as a driver of sales and earnings growthfor private equity the merlinnexus objective is to realize longterm capital appreciation from investments in latestage private companies pipes private investments in public entities and select open market transactions the fund is invested in all segments of the healthcare industry with an emphasis on productdriven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs partner    oracle corp oracle corp provides enterprise software and computer hardware products and services the company is organized into the following businesses software and cloud hardware systems and services the software and cloud business operates through the following segments new software licenses and cloud software subscriptions cloud infrastructureasaservice and software license updates and product support the new software licenses and cloud software subscriptions segment includes database middleware and application software licenses as well as its oracle cloud softwareasaservice and platformasaservice offerings the cloud infrastructureasaservice segment provides deployment and management offerings for its software and hardware and related it infrastructure the software license updates and product support segment provide customers with rights to software product upgrades and maintenance releases and patches released during the term of the support period the hardware systems business operates through the following segments hardware systems products and hardware systems support the hardware systems products segment provides a broad selection of hardware systems and related services including servers storage networking virtualization software operating systems and management software to support diverse it environments including cloud computing environments the hardware systems support segment provides customers with software updates for software components that are essential to the functionality of its server and storage products such as oracle solaris and certain other software products and can include product repairs maintenance services and technical support services the services business offer services solutions to help customers and partners maximize the performance of their investments in oracle technology oracle corp was founded on june   by lawrence joseph ellison robert nimrod miner and edward a oates and is headquartered in redwood city ca partner    harpel advisory co inc harpel specializes in investing in liquid financial assets senior biotechnology analyst    merrill lynch investment managers inc mlams worldwide approach to equity investing uses a philosophy of identifying relative value among individual stocks and stock markets by focusing primarily on two variables reinvestment rate and the pricetobook value ratiothere are seven additional screens employed to further refine the process the factors used to identify value include pricetocash flow pricetoearnings ratios past and future earnings growth and dividend payouts for asset allocation a country whose market valuation measurements seem consistently above or below world averages or its own historical averages are over or underweighted accordingly the degrees of over or underweighting are determined by relative economic prospects as measured by the outlook for gnp inflation and interest rates of each country and their impact on currency movementsby combining a value approach to individual stock selection with asset allocation by country the firm seeks to achieve consistent performance relative to international equity indexesmlam combines topdown and bottomup analysis and uses proprietary models as part of their research process their funds are teammanaged biotechnology analyst    prudentialbache securities canada ltd research fellow    cold spring harbor laboratory cold spring harbor laboratory inc provides research services it operates educational institutions the firm offers research in cancer neurobiology plant genetics and bioinformatics it also offers laboratory workshops to science teachers students and other groups across the nation the company was founded in  and is headquartered in cold spring harbor ny research fellow    mrc laboratory of molecular biology mrc laboratory of molecular biology provides biological research and development services it also offers methods for determining the threedimensional structures of proteins and other macromolecules the sequencing of dna and the development of monoclonal antibodies the company was founded by max ferdinand perutz in  and is headquartered in cambridge the united kingdom founder prior merlin biomed group llc merlin biomed group llc is a venture capitalprivate equity firm located in new york city boards  committees nonprofit boards ▾ member deans council current princeton university princeton university is a vibrant community of scholarship and learning that stands in the nations service and in the service of all nations chartered in  princeton is the fourtholdest college in the united states princeton is an independent coeducational nondenominational institution that provides undergraduate and graduate instruction in the humanities social sciences natural sciences and engineering as a worldrenowned research university princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding at the same time princeton is distinctive among research universities in its commitment to undergraduate teaching today more than  faculty members instruct approximately  undergraduate students and  graduate students the universitys generous financial aid program ensures that talented students from all economic backgrounds can afford a princeton education political donations   jon m huntsman jr former governor of utah   charles e schumer minority leader at office of the senate minority leader charles schumer transactions details hidden iguana healthcare partners ltd raised money in a private placement transaction other affiliations stuart terry weisbrod is affiliated with iguana healthcare partners llc iguana healthcare management llc merlin biomed group hedge funds oracle corp harpel advisory co inc merrill lynch investment managers inc prudentialbache securities canada ltd cold spring harbor laboratory mrc laboratory of molecular biology merlin biomed group llc princeton university youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft iguana healthcare management reviews  financial advisory firm iguana healthcare management iguanahealthcaremanagement rating       your rating  reviews  submit your rating httpiguanahealthcarecom claim this profile     info  reviews     activity     answers iguana healthcare management reviews  info iguana healthcare managements primary clients are corporations investment vehicles or other businessessee more other names used iguana healthcare management llc advisors that work at iguana healthcare management contact  west putnam ave nd floor greenwich ct  main number  categories na   iguana healthcare management review highlights total recommendations  recommend  iguana healthcare management reviews no reviews found for iguana healthcare management be the first to write a review follow  followers  following ask iguana healthcare management a question send iguana healthcare management a direct message this correspondence is public instead send a direct message this is a direct message instead ask a public question or sign in post my question send message  share or get your friends opinion about iguana healthcare management wallet points qa  followers  misc  total  im following no users followed information on this page is provided as is and solely for informational purposes not for any other purpose or advice in addition this information does not originate from us and thus we do not guarantee its accuracy you can check the profile page of each professional or company to determine whether they are a paying advertiser indicated by the word sponsored regardless of advertiser status none of the listings reviews or other information on wallet hub constitutes in any way a referral or endorsement by us of the respective financial company or professional or vice versa furthermore it is important to note that the inclusion of a financial company or professional on wallet hub does not necessarily indicate their involvement with the site or control over the information that we display information is displayed first and foremost for the benefit of consumers report abuse reviews get your free credit score  report join wallethub   free  unlimited credit reports  unlimited credit scores  credit monitoring protection  credit improvement tips  automatically finds savings sign up for free no credit card needed zynerba pharmaceuticals nasdaqzyne stock price news  analysis zynerba pharmaceuticals company profile nasdaqzyne company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about zynerba pharmaceuticals nasdaqzyne zynerba pharmaceuticals inc is a specialty pharmaceutical company the company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs its development pipeline includes two product candidates zyn and zyn zyn is a synthetic cannabidiol cbd which is a nonpsychoactive cannabinoid formulated as a patentprotected permeationenhanced gel for transdermal delivery through the skin and into the circulatory system zyn is in phase ii clinical development in patients with refractory epilepsy in patients with osteoarthritis of the knee as well as in patients with fragile x syndrome zyn is a prodrug of tetrahydrocannabinol thc that enables transdermal delivery through the skin and into the circulatory system through a patch zyn is targeting two pain indications fibromyalgia and peripheral neuropathic pain industry sector and symbol sector medical industry biotechnology  medical research  nec subindustry na symbol nasdaqzyne cusip na web wwwzynerbacom capitalizationmarket cap  millionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio naforeward pe ratio pe growth sales  book valueannual revenue naprice  sales nabook value  per shareprice  book  profitabilityebidta return on equity return on assets debtcurrent ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for zynerba pharmaceuticals nasdaqzyne what is zynerba pharmaceuticals stock symbol zynerba pharmaceuticals trades on the nasdaq under the ticker symbol zyne how were zynerba pharmaceuticals earnings last quarter zynerba pharmaceuticals inc nasdaqzyne released its earnings results on tuesday may th the company reported  earnings per share eps for the quarter missing the thomson reuters consensus estimate of  by  view zynerba pharmaceuticals earnings history when will zynerba pharmaceuticals make its next earnings announcement zynerba pharmaceuticals is scheduled to release their next quarterly earnings announcement on wednesday august th  view earnings estimates for zynerba pharmaceuticals where is zynerba pharmaceuticals stock going where will zynerba pharmaceuticals stock price be in   analysts have issued  month price objectives for zynerba pharmaceuticals stock their forecasts range from  to  on average they expect zynerba pharmaceuticals share price to reach  in the next year view analyst ratings for zynerba pharmaceuticals what are analysts saying about zynerba pharmaceuticals stock here are some recent quotes from research analysts about zynerba pharmaceuticals stock  according to zacks investment research zynerba pharmaceuticals inc is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery its product candidates which are in clinical trial stage include zyn and zyn synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy fragile x syndrome osteoarthritis fibromyalgia and peripheral neuropathic pain zynerba pharmaceuticals inc is headquartered in devon pennsylvania    maxim group analysts commented zynerba announced the completion of target pediatric patient enrollment n ages from  –  years old in the phase ii fabc treatment of fragile x syndrome anxiety and behavioral challenges with cbd study to evaluate zyn zynerba’s cannabidiol cbd gel in children with fragile x syndrome fxs  who are some of zynerba pharmaceuticals key competitors some companies that are related to zynerba pharmaceuticals include inovio pharmaceuticals ino adamas pharmaceuticals adms pdl biopharma pdli abeona therapeutics abeo concert pharmaceuticals cnce celyad sa cyad puretech health plc prtc curis cris celldex therapeutics cldx idera pharmaceuticals idra advaxis adxs novavax nvax codexis cdxs corvus pharmaceuticals crvs voyager therapeutics vygr horizon discovery group plc hzd newlink genetics corporation nlnk and protagonist therapeutics ptgx who are zynerba pharmaceuticals key executives zynerba pharmaceuticals management team includes the folowing people armando anido chairman of the board chief executive officerterri b sebree presidentjames e fickenscher chief financial officer vice president  corporate developmentsuzanne m hanlon secretary general counsel and vice president human resourceswilliam roberts vice president  investor relations and corporate communicationsray mannion vice president  manufacturingbrian rosenberger vice president  commercialwarren d cooper md lead independent directorwilliam j federici independent directorthomas l harrison independent director when did zynerba pharmaceuticals ipo zyne raised  million in an initial public offering ipo on wednesday august th  the company issued  shares at  per share jefferies and piper jaffray served as the underwriters for the ipo and canaccord genuity and oppenheimer  co were comanagers who owns zynerba pharmaceuticals stock zynerba pharmaceuticals stock is owned by a number of of retail and institutional investors top institutional shareholders include pennsylvania trust co  and rothschild investment corp il  company insiders that own zynerba pharmaceuticals stock include armando anido james e fickenscher michael rapp and suzanne m hanlon view institutional ownership trends for zynerba pharmaceuticals who bought zynerba pharmaceuticals stock who is buying zynerba pharmaceuticals stock zynerba pharmaceuticals stock was purchased by a variety of institutional investors in the last quarter including pennsylvania trust co and rothschild investment corp il company insiders that have bought zynerba pharmaceuticals stock in the last two years include armando anido james e fickenscher and michael rapp view insider buying and selling for zynerba pharmaceuticals how do i buy zynerba pharmaceuticals stock shares of zynerba pharmaceuticals can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is zynerba pharmaceuticals stock price today one share of zynerba pharmaceuticals stock can currently be purchased for approximately  marketbeat community rating for zynerba pharmaceuticals nasdaq zynecommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about zynerba pharmaceuticals and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for zynerba pharmaceuticals nasdaqzyne how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for zynerba pharmaceuticals nasdaqzyne show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsjefferies group llcreiterated ratingbuymediummaxim groupset price targetbuynaroth capitalset price targetbuyhighcantor fitzgeraldset price targetbuylowcanaccord genuityset price targetbuylowoppenheimer holdings incset price targetbuylowhc wainwrightreiterated ratingbuy  buy  highpiper jaffray companiesreiterated ratingoverweightnadata available from  forward earnings earnings history for zynerba pharmaceuticals nasdaqzyneearnings history by quarter for zynerba pharmaceuticals nasdaq zynedatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsnaq  millionviewnaq viewnaq  millionviewnaq millionviewnaq million millionviewnaq million millionviewnaq millionviewnadata available from  forward estimates earnings estimates for zynerba pharmaceuticals nasdaqzyne eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q data provided by zacks investment research dividends dividend history for zynerba pharmaceuticals nasdaqzyneno dividend announcements for this company have been tracked by marketbeatcom insider trades insider trading and institutional ownership history for zynerba pharmaceuticals nasdaqzyneinsider ownership percentage institutional ownership percentage insider trades by quarter for zynerba pharmaceuticals nasdaqzynetransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsarmando anidochairmanbuy  james e fickenschercfobuy  michael rappmajor shareholderbuy  james e fickenschercfobuy  suzanne m hanloninsidersell  data available from  forward headlines headline trends for zynerba pharmaceuticals nasdaqzyne latest headlines for zynerba pharmaceuticals nasdaqzyne source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinezynerba pharmaceuticals inc zyne receives average rating of buy from analystswwwamericanbankingnewscom  july  at  pmzynerba pharmaceuticals mourns passing of director cynthia a rask  nasdaqwwwnasdaqcom  july  at  pmzynerba pharma zyne announces passing of director cynthia a raskwwwstreetinsidercom  july  at  amzynerba pharmaceuticals mourns passing of director cynthia a raskfinanceyahoocom  july  at  ambiotech players lead the growth charge in the legal cannabis market  pr newswire press releasewwwprnewswirecom  july  at  amthese  marijuana stocks all jumped at least  last weekfinanceyahoocom  july  at  ambillionaires bet big on canadas newest  billion market  pr newswire press releasewwwprnewswirecom  july  at  pmzynerba pharmaceuticals inc nasdaqzyne upgraded to hold at zacks investment researchwwwamericanbankingnewscom  july  at  pmzynerba pharmaceuticals inc nasdaqzyne raised to hold at bidaskclubwwwamericanbankingnewscom  july  at  pmtop biotech manager sells arena pharmaceuticals on todays big gainfinanceyahoocom  july  at  pmtodays research reports on trending tickers insys therapeutics and zynerba pharmaceuticalsfinanceyahoocom  july  at  amzynerba pharmaceuticals inc nasdaqzyne earns buy rating from jefferies group llcwwwamericanbankingnewscom  july  at  ammaking rounds chop doc honored zynerba making progress pcom gets m giftwwwbizjournalscom  july  at  amzynerba pharmaceuticals inc nasdaqzyne given consensus recommendation of buy by brokerageswwwamericanbankingnewscom  july  at  pm marijuana stocks looking to combat the opioid epidemicfinanceyahoocom  july  at  ammarijuana could help treat alzheimers heres how it would work  benzingawwwbenzingacom  june  at  pmzynerba pharmaceuticals added to the russell ® index  globenewswire press releaseglobenewswirecom  june  at  amzynerba pharmaceuticals initiates zyn phase  clinical programfinanceyahoocom  june  at  amzynerba pharmaceuticals added to the russell ® indexfinanceyahoocom  june  at  amcantor fitzgerald weighs in on zynerba pharmaceuticals incs fy earnings zynewwwamericanbankingnewscom  june  at  amgenomic health ghdx and zynerba pharmaceuticals zyne headtohead comparisonwwwamericanbankingnewscom  june  at  pmcomparing the medicines company mdco  zynerba pharmaceuticals zynewwwamericanbankingnewscom  june  at  pmreviewing fibrocell science fcsc and zynerba pharmaceuticals zynewwwamericanbankingnewscom  june  at  ammaxim bullish on zynerba pharmaceuticals inc zyne following meeting with managementfinanceyahoocom  june  at  pmroth capital analysts give zynerba pharmaceuticals inc zyne a  price targetwwwamericanbankingnewscom  june  at  pmzynerba pharmaceuticals inc zyne pt set at  by cantor fitzgeraldwwwamericanbankingnewscom  june  at  amzynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome  globenewswire press releaseglobenewswirecom  june  at  ambiotechnology  medical researchwwwreuterscom  june  at  amzynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndromefinanceyahoocom  june  at  ammaxim group reaffirms buy rating for zynerba pharmaceuticals inc zynewwwamericanbankingnewscom  june  at  pmzynerba pharmaceuticals inc zyne receives consensus recommendation of buy from brokerageswwwamericanbankingnewscom  june  at  pmbetter know a marijuana stock zynerba pharmaceuticals  motley foolwwwfoolcom  june  at  amzynerba pharmaceuticals to present at the jefferies  global   nasdaqwwwnasdaqcom  june  at  amzynerba pharmaceuticals to present at the jefferies  global healthcare conferencefinanceyahoocom  june  at  amzynerba pharmaceuticals inc zyne downgraded by zacks investment researchwwwamericanbankingnewscom  may  at  amzynerba pharmaceuticals zyne buy rating reaffirmed at jefferies group llcwwwamericanbankingnewscom  may  at  pmzynerba pharmaceuticals inc zyne cfo purchases  in stockwwwamericanbankingnewscom  may  at  amzynerba pharmaceuticals inc zyne chairman buys  in stockwwwamericanbankingnewscom  may  at  amcantor fitzgerald comments on zynerba pharmaceuticals incs fy earnings zynewwwamericanbankingnewscom  may  at  amzynerba pharmaceuticals inc zyne given consensus recommendation of buy by analystswwwamericanbankingnewscom  may  at  pmzynerba pharmaceuticals inc zyne to post q  earnings of  per share oppenheimer holdings forecastswwwamericanbankingnewscom  may  at  amjefferies group brokers reduce earnings estimates for zynerba pharmaceuticals inc zynewwwamericanbankingnewscom  may  at  amzynerba reports q lossfinanceyahoocom  may  at  amzynerba pharmaceuticals inc zyne releases quarterly earnings results misses estimates by  epswwwamericanbankingnewscom  may  at  pmzynerba pharmaceuticals reports first quarter  financial results and operational highlightsglobenewswirecom  may  at  amcantor fitzgerald analysts give zynerba pharmaceuticals inc zyne a  price targetwwwamericanbankingnewscom  may  at  pmcatalysts growing like weeds for zynerba next quarterfeedsbenzingacom  may  at  pmbriefzynerba pharmaceuticals reports q loss per share   reuterswwwreuterscom  may  at  amzynerba pharmaceuticals reports first quarter  financial results and operational highlights  nasdaqwwwnasdaqcom  may  at  amzynerba pharmaceuticals reports first quarter  financial results and operational highlightsfinanceyahoocom  may  at  am social chart zynerba pharmaceuticals zyne chart for saturday july   this page was last updated on  by marketbeatcom staff zynerba pharmaceuticals inc zyne upgraded by zacks investment research to hold  daily political home aboutcontact columnists privacy policy headlines politics nation world issues economy finance zynerba pharmaceuticals inc  get news  ratings daily enter your email address below to get the latest news and analysts ratings for zynerba pharmaceuticals inc with our free daily email newsletter follow dailypolitical     latest news nestle sa nesn given a chf  price target at ubs ag astrazeneca plc azn insider acquires £ in stock blackrock throgmorton trust plc lonthrg insider christopher samuel acquires  shares of stock brave bison group plc lonbbsn scheduled to post earnings on monday colefax group plc loncfx upgraded at peel hunt connect group plc cnct price target lowered to gbx  at j p morgan chase  co margherita d valle purchases  shares of centrica plc loncna stock manvinder singh banga purchases  shares of glaxosmithkline plc longsk stock shawbrook group plc lonshaw insider angela wakelin sells  shares raymond james financial inc trims united community banks inc ucbi target price to  tractor supply’s nasdaqtsco hold rating reaffirmed at deutsche bank ag trovagene inc trov given a  price target by maxim group analysts tcp capital corp nasdaqtcpc lowered to “strong sell” at bidaskclub zacks investment research downgrades hilton worldwide holdings inc nysehlt to hold imperial capital begins coverage on shotspotter inc ssti wpcs international wpcs getting somewhat favorable press coverage accern reports atlas energy group atls receiving favorable news coverage report shows prana biotechnology nasdaqpran earning somewhat positive news coverage analysis shows mitie group plc’s mto “buy” rating reaffirmed at canaccord genuity jupiter fund management plc lonjup price target raised to gbx  at credit suisse group zynerba pharmaceuticals inc zyne upgraded by zacks investment research to “hold” july th    comments  filed under  by stacy sanders filed under analyst articles  us  finance tweet zacks investment research upgraded shares of zynerba pharmaceuticals inc nasdaqzyne from a sell rating to a hold rating in a research note published on thursday according to zacks “zynerba pharmaceuticals inc is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery its product candidates which are in clinical trial stage include zyn and zyn synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy fragile x syndrome osteoarthritis fibromyalgia and peripheral neuropathic pain zynerba pharmaceuticals inc is headquartered in devon pennsylvania “ a number of other research firms also recently weighed in on zyne bidaskclub raised shares of zynerba pharmaceuticals from a sell rating to a hold rating in a research report on wednesday cantor fitzgerald set a  target price on shares of zynerba pharmaceuticals and gave the company a buy rating in a research report on monday march th oppenheimer holdings inc set a  target price on shares of zynerba pharmaceuticals and gave the company a buy rating in a research report on saturday april st canaccord genuity set a  price objective on shares of zynerba pharmaceuticals and gave the company a buy rating in a research report on saturday may th finally jefferies group llc reissued a buy rating and issued a  price objective on shares of zynerba pharmaceuticals in a research report on thursday may th two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock the company currently has an average rating of buy and an average target price of  zynerba pharmaceuticals nasdaqzyne traded up  during midday trading on thursday hitting   shares of the company traded hands the stock’s day moving average is  and its day moving average is  zynerba pharmaceuticals has a month low of  and a month high of  the firm’s market capitalization is  million zynerba pharmaceuticals nasdaqzyne last released its earnings results on tuesday may th the company reported  earnings per share for the quarter missing analysts’ consensus estimates of  by  analysts anticipate that zynerba pharmaceuticals will post  eps for the current fiscal year copyright violation warning “zynerba pharmaceuticals inc zyne upgraded by zacks investment research to “hold”” was originally published by daily political and is the sole property of of daily political if you are accessing this news story on another domain it was illegally stolen and reposted in violation of us and international trademark and copyright law the original version of this news story can be read at httpswwwdailypoliticalcomzynerbapharmaceuticalsinczyneupgradedbyzacksinvestmentresearchtoholdhtml in related news chairman armando anido bought  shares of the business’s stock in a transaction dated monday may th the stock was bought at an average price of  per share for a total transaction of  following the purchase the chairman now owns  shares in the company valued at approximately  the transaction was disclosed in a filing with the securities  exchange commission which is available through this hyperlink also cfo james e fickenscher bought  shares of the business’s stock in a transaction dated friday may th the shares were bought at an average price of  per share with a total value of  following the purchase the chief financial officer now owns  shares in the company valued at approximately  the disclosure for this purchase can be found here company insiders own  of the company’s stock several hedge funds have recently bought and sold shares of the company pennsylvania trust co bought a new stake in zynerba pharmaceuticals during the second quarter worth about  fny managed accounts llc bought a new stake in zynerba pharmaceuticals during the first quarter worth about  iguana healthcare management llc bought a new stake in zynerba pharmaceuticals during the first quarter worth about  morgan stanley boosted its stake in zynerba pharmaceuticals by  in the first quarter morgan stanley now owns  shares of the company’s stock worth  after buying an additional  shares in the last quarter finally geode capital management llc boosted its stake in zynerba pharmaceuticals by  in the first quarter geode capital management llc now owns  shares of the company’s stock worth  after buying an additional  shares in the last quarter institutional investors own  of the company’s stock zynerba pharmaceuticals company profile zynerba pharmaceuticals inc is a specialty pharmaceutical company the company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs its development pipeline includes two product candidates zyn and zyn zyn is a synthetic cannabidiol cbd which is a nonpsychoactive cannabinoid formulated as a patentprotected permeationenhanced gel for transdermal delivery through the skin and into the circulatory system get a free copy of the zacks research report on zynerba pharmaceuticals zyne for more information about research offerings from zacks investment research visit zackscom receive news  ratings for zynerba pharmaceuticals inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for zynerba pharmaceuticals inc and related companies with marketbeatcoms free daily email newsletter  comment on this post click here to cancel reply name required mail will not be published required website wordpress hashcash needs javascript to work but your browser has javascript disabled your comment will be placed in moderation latest news jeff sessions spoke of resigning after tensions increase with trump president trump’s tweets complicate already complicated week world leaders very critical of paris agreement decision by trump aide to president trump resigns with more expected scudclass missile launched by north korea  dailypolitical llc  all rights reserved privacy policy  about  columnists  contact iguana healthcare management llc institutional portfolio  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  institutional portfolio iguana healthcare management llc  fifth avenue new york new york    report date  position statistics total positions  new positions  increased positions  decreased positions  positions with activity  sold out positions  total mkt value in  millions  institutional holdings information is filed by major institutions on form f with the securities and exchange commission sector weighting energy basic materials industrials consumer cyclicals consumer noncyclicals  financials  healthcare  technology telecommunication services utilities total positions new increased decreased activity sold out  positions as of  company class value of shares s ▼ change in value s change  shares held celgene corp com     shire plc sponsored adr   new  medicines co com     amgen inc com  new  merck  co inc com     aetna inc new com   new  alexion pharmaceuticals inc com     global blood therapeutics inc com     ultragenyx pharmaceutical inc com     km group hldgs inc com     clovis oncology inc com     aerie pharmaceuticals inc com     allergan plc shs     glaukos corp com     dermira inc com     supernus pharmaceuticals inc com     esperion therapeutics inc new com   new  abbott labs com     nuvasive inc com     immunomedics inc com      first previousnext last  latest news headlines sprint proposes merger with charter communications  wsj pm et   reuters union cheers as trucks kept out of us selfdriving legislation pm et   reuters rpthundreds of us counties at risk for no obamacare insurer in  pm et   reuters wells fargo faces angry questions after new sales abuses uncovered pm et   reuters us regulators weigh future of appeal in metlife case pm et   reuters view all latest headlines closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex